Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as zamtocabtagene autoleucel (MB-CART2019.1)
zamtocabtagene autoleucel · 1 trial · 1 indication
The primary efficacy outcome of this study is BORR, defined as the proportion of subjects with at least one partial response (PR) or complete response (CR) from MB-CART2019.1 infusion until progressive disease (PD), start of new anti-lymphoma therapy, lost to follow-up or death, whichever occurs first.
The primary safety outcome of this study is to evaluate the incidence, type, frequency, and severity of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESI) associated with the study product.
| Arm | Type | Description |
|---|---|---|
| zamtocabtagene autoleucel (MB-CART2019.1) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| zamtocabtagene autoleucel (MB-CART2019.1) | DRUG | Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy. |
Inclusion Criteria: 1. Is able to provide age-appropriate assent/consent (as applicable, according to local legislation) and/or have a guardian able to provide consent signed and dated by the parent(s) or by subject's legal guardian before conduct of any study-specific procedures. 2. Has histologic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Zamtocabtagene autoleucel is an investigational cell therapy being studied for the treatment of B-cell neoplasms, specifically in pediatric patients with relapsed or refractory disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Zamtocabtagene autoleucel is a cell therapy, a class of treatment that uses modified cells to fight cancer. Its specific molecular target is not disclosed in available information, but it is being evaluated for its safety and efficacy in B-cell neoplasms.
Zamtocabtagene autoleucel is being developed by Thermo Fisher Scientific Inc, a company traded on the New York Stock Exchange under the ticker symbol TMO. The drug is also known as MB-CART2019.1.
Zamtocabtagene autoleucel is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory bodies and is still being studied in clinical trials.
Zamtocabtagene autoleucel is being studied in a Phase 2 clinical trial with the identifier NCT06508931. This trial is recruiting pediatric patients with relapsed or refractory B-cell neoplasms and is being conducted in France, Germany, Italy, and the Netherlands.
Yes, zamtocabtagene autoleucel is also known as MB-CART2019.1. Both names refer to the same investigational cell therapy being developed for the treatment of B-cell neoplasms.